A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension

Clinical Ophthalmology

Volumn 3, Issue 1, 2009, Pages 189-194

  Godfrey, David A ^a   Peplinski, Lee S ^b   Stewart, Jeanette A ^c   Stewart, William C ^c  

^a Glaucoma Associates of Texas   (United States)

^b Kentuckiana Institute for Eye Research   (United States)

^c University of South Carolina   (United States)

Author keywords

Comfort; Glaucoma; Latanoprost; Ocular hypertension; Travoprost BAK free

Indexed keywords

ANTIGLAUCOMA AGENT; BENZALKONIUM CHLORIDE; BRINZOLAMIDE; DORZOLAMIDE; LATANOPROST; TRAVATAN Z; TRAVOPROST; UNCLASSIFIED DRUG;

ABNORMAL SENSATION; ARTICLE; BURNING SENSATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRY EYE; EYE DISCOMFORT; EYE TOXICITY; FEMALE; HUMAN; HYPERTRICHOSIS; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; PATIENT ATTITUDE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SAFETY; VISUAL ANALOG SCALE;

EID: 77953458165     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Stewart WC. Clinical Practice of Glaucoma. Thorofare, NJ: SLACK, Inc; 1990.
2. Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol. 2005;5:459-463.
3. Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma. 2003;12:486-490.
4. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11:119-126.
5. Lewis RA, Katz GJ, Weiss MJ, et al; Travoprost BAC-free Study Group. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007;16:98-103.
6. Stewart WC, Pfieffer N, Mathis HM. Meta-analysis of articles evaluating routine intraocular pressure control for monotherapy in the United States and Germany. Eur J Ophthalmol. 2009. In press.
7. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology. 1996;103:1916-1924.
8. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118:615-621.
9. Rosner B. Fundamentals of Biostatistics. Boston, MA: Duxbury Press; 1982. p. 301-304.
10. Stewart WC, Day DG, Stewart JA, Holmes KT, Jenkins JN. Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% versus placebo in primary open-angle glaucoma and ocular hypertension subjects. Eye. 2004;18:905-910.
11. Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol. 1997;41(Suppl 2):S105-S110.
12. Siegel S. Non Parametric Statistics. Series in Psychology. New York, NY: McGraw Hill; 1956. p. 63-67.
13. Stewart WC, Stewart JA, Leech JN. Acute and chronic ocular symptoms of dorzolamide 2% compared with placebo. J Glaucoma. 2003;12:151-155.
14. Book SA. Essentials of Statistics. New York, NY: McGraw Hill Book Company; 1978.
15. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350-355.
16. Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86:716-726.
17. Baudouin C, Riancho L, Warnet J-M, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: Travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007;48:4123-4128.
18. Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther. 2006;23:511-519.
19. Kahook M, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008;27:339-343.
20. Henry JC, Peace JH, Stewart JA, Stewart WC. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol. 2008;2:613-621.
21. Stewart WC, Stewart JA, Leech JN, Jackson AL. Corneal punctate staining with latanoprost, bimatoprost and travoprost. J Glaucoma. 2003;12:475-479.
22. McCarey B, Edelhauser H. In vivo corneal epithelial permeability following treatment with prostaglandin analogs with or without benzalkonium chloride. J Ocul Pharmacol Ther. 2007;23:445-451.
23. Day DG, Sharpe ED, Atkinson MJ, Stewart JA, Stewart WC. The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients. Eye. 2006;20:583-590.
24. Freeman EE, Muñoz B, West SK, Jampel HD, Friedman DS. Glaucoma and quality of life: the Salisbury Eye Evaluation. Ophthalmology. 2008;115:233-238.